featured
Abiraterone Acetate Plus Prednisolone With or Without Enzalutamide for Patients With Metastatic Prostate Cancer Starting ADT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
Lancet Oncol 2023 May 01;24(5)443-456, G Attard, L Murphy, NW Clarke, A Sachdeva, C Jones, A Hoyle, W Cross, RJ Jones, CC Parker, S Gillessen, A Cook, C Brawley, C Gilson, H Rush, H Abdel-Aty, CL Amos, C Murphy, S Chowdhury, Z Malik, JM Russell, N Parkar, C Pugh, C Diaz-Montana, C Pezaro, W Grant, H Saxby, I Pedley, JM O'Sullivan, A Birtle, J Gale, N Srihari, C Thomas, J Tanguay, J Wagstaff, P Das, E Gray, M Alzouebi, O Parikh, A Robinson, AH Montazeri, J Wylie, A Zarkar, R Cathomas, MD Brown, Y Jain, DP Dearnaley, MD Mason, D Gilbert, RE Langley, R Millman, D Matheson, MR Sydes, LC Brown, MKB Parmar, ND JamesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.